Colon Cancer Clinical Trial
AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test
Summary
Freenome is using a type of artificial intelligence, called machine learning, to identify patterns of cell-free biomarkers in blood to detect cancer early. The purpose of this study is to develop and validate a blood-based assay to detect colorectal cancer by collecting blood and stool samples from healthy patients undergoing routine screening colonoscopy and from patients recently diagnosed with colorectal cancer or advanced adenomas.
Full Description
Early detection of cancer combined with effective treatment improves survival and quality of life. Freenome is using a type of artificial intelligence, called machine learning, to identify patterns of cell-free biomarkers in the blood to detect cancer early. The purpose of this study is to develop and validate a blood-based assay for the early detection of colorectal cancer. The study will collect blood and stool samples from healthy patients undergoing routine screening colonoscopy and from patients recently diagnosed with colorectal cancer or advanced adenomas. A blood-based test for colorectal cancer and pre-cancerous lesions could offer an accurate, convenient, and patient-friendly screening option for current and future generations, and, in doing so, could save and improve lives by increasing adherence and early detection.
Freenome is looking for three types of patients in this study:
Cohort A:
People ages 50-84 who have been recently diagnosed with (or strong clinical suspicion for) colorectal cancer or advanced adenoma. Blood samples must be collected before any cancer treatment has been initiated.
Cohort B:
People ages 50-84 undergoing routine screening colonoscopies for colorectal cancer as part of their regular medical check-ups. Blood samples must be collected before bowel preparation for the colonoscopy.
Cohort C:
People 18 years or older who have been recently diagnosed with (or strong clinical suspicion for) colorectal cancer or advanced adenoma. Blood samples must be collected before any cancer treatment has been initiated.
Eligibility Criteria
COHORT A
Inclusion Criteria:
50-84 years of age (inclusive) at the time of screening
Recently diagnosed with (or strong clinical suspicion for) primary colorectal cancer or advanced adenoma with plans to surgically or endoscopically remove the target lesion(s)
At least 7 days before but no more than 6 months after the most recent colonoscopy
Able and willing to provide blood and stool (optional) samples per protocol
Able to comprehend and willing to sign and date the written informed consent document(s) and any applicable medical record release documents for the study
Key Exclusion Criteria:
Personal history of colorectal cancer, colorectal adenomas (excluding non-adenomatous (e.g., hyperplastic polyps)) or aerodigestive tract cancer (other than most recent diagnosis)
Colonoscopy within the previous 9 years (other than most recent diagnosis)
Overt rectal bleeding within the previous 30 days
Have a medical condition which, in the opinion of the investigator, should preclude enrollment into the study.
Have participated or be currently participating in a clinical research study in which an experimental medication has been administered during the 60 days up to and including the date of providing informed consent or may be administered through the time of the colonoscopy.
If female, known to be pregnant.
COHORT B
Inclusion Criteria:
50-84 years of age (inclusive) at the time of screening
Planning to undergo a screening colonoscopy within 75 days after providing signed informed consent
Able and willing to provide blood and stool (optional) samples per protocol
Able to comprehend and willing to sign and date the written informed consent document(s) and any applicable medical record release documents for the study
Key Exclusion Criteria:
Personal history of colorectal cancer, colorectal adenoma (excluding non-adenomatous (e.g., hyperplastic polyps)) or aerodigestive tract cancer
Colonoscopy within the previous 9 years
Overt rectal bleeding within the previous 30 days
Have a medical condition which, in the opinion of the investigator, should preclude enrollment into the study.
Have participated or be currently participating in a clinical research study in which an experimental medication has been administered during the 60 days up to and including the date of providing informed consent or may be administered through the time of the colonoscopy.
If female, known to be pregnant.
COHORT C
Inclusion Criteria:
At least 18 years of age (inclusive) at the time of screening
Recently diagnosed with (or strong clinical suspicion for) primary colorectal cancer or advanced adenoma with plans to surgically or endoscopically remove the target lesion(s)
At least 7 days before but no more than 6 months after the most recent colonoscopy
Able and willing to provide blood and stool (optional) samples per protocol
Able to comprehend and willing to sign and date the written informed consent document(s) and any applicable medical record release documents for the study
Exclusion Criteria:
Have a medical condition which, in the opinion of the investigator, should preclude enrollment into the study.
Have participated or be currently participating in a clinical research study in which an experimental medication has been administered during the 60 days up to and including the date of providing informed consent or may be administered through the time of the colonoscopy.
If female, be known to be pregnant.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 30 Locations for this study
Huntsville Alabama, 35801, United States
Chandler Arizona, 85224, United States
Tucson Arizona, 85710, United States
Tucson Arizona, 85745, United States
Little Rock Arkansas, 72211, United States
Chula Vista California, 91910, United States
Oxnard California, 93030, United States
San Diego California, 92114, United States
Bridgeport Connecticut, 06606, United States
Hialeah Florida, 33016, United States
Homestead Florida, 33030, United States
Palm Harbor Florida, 34684, United States
Rockford Illinois, 61107, United States
Bastrop Louisiana, 71220, United States
Metairie Louisiana, 70006, United States
Shreveport Louisiana, 71105, United States
Brockton Massachusetts, 02302, United States
Omaha Nebraska, 68114, United States
Asheville North Carolina, 28801, United States
Chapel Hill North Carolina, 27599, United States
Fayetteville North Carolina, 28304, United States
Raleigh North Carolina, 27612, United States
Wilmington North Carolina, 28403, United States
Jackson Tennessee, 38305, United States
Ogden Utah, 84405, United States
Chesapeake Virginia, 23320, United States
Fairfax Virginia, 22031, United States
Norfolk Virginia, 23502, United States
Bellevue Washington, 98004, United States
Calgary Alberta, T2N 4, Canada
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.